Literature DB >> 24804748

The importance and challenge of pediatric trials of hemophilia drugs.

Dirk Mentzer1, Emilie Desfontaine2, Paolo A Tomasi2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24804748     DOI： 10.1038/nm.3546

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  4 in total

1.  The changing prognosis of classic hemophilia (factor VIII "deficiency").

Authors:  P K Jones; O D Ratnoff
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

2.  Comment on: Mannucci, P. M. Evolution of the European guidelines for the clinical development of factor VIII products.

Authors:  A Hilger; C Arras-Reiter; B Keller-Stanislawski; B Ljungberg; C Male; D Mentzer; R Seitz; G Silvester
Journal:  Haemophilia       Date:  2013-05       Impact factor: 4.287

3.  Pediatric requirements in Europe stymie help for hemophilia.

Authors:  Flora Peyvandi; Frits R Rosendaal; Brian O'Mahony; Pier Mannuccio Mannucci
Journal:  Nat Med       Date:  2014-02       Impact factor: 53.440

Review 4.  Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management.

Authors:  P M Mannucci
Journal:  Haemophilia       Date:  2012-10-23       Impact factor: 4.287
  4 in total
  2 in total

1.  Reply to: The importance and challenge of pediatric trials of hemophilia drugs.

Authors:  Flora Peyvandi; Frits R Rosendaal; Brian O'Mahony; Pier Mannuccio Mannucci
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

Review 2.  Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.

Authors:  Paolo A Tomasi; Gunter F Egger; Chrissi Pallidis; Agnes Saint-Raymond
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.